Prognostic Role of Lymphocyte/Monocyte Ratio in Chronic Lymphocytic Leukemia.

J Hematol

Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Fatih, Istanbul, Turkey.

Published: December 2020

Background: Chronic lymphocytic leukemia (CLL) is a B-lymphoproliferative disease with varying clinical characteristics, which occurs mostly in older ages. In studies from literature, we see that different parameters are examined to determine the prognosis of CLL. The main purpose of our study is to determine the relationship of lymphocyte/monocyte ratio (LMR) value in CLL, which has been previously shown to be a prognostic factor in various solid organ tumors and some hematological malignancies.

Methods: A total of 173 patients who were followed up between 2005 and 2019 were retrospectively analyzed. The diagnostic age, gender, laboratory, absolute lymphocyte and monocyte count, LMR and overall survival (OS), treatment and responses, recurrence, cytogenetic subtype and mortality rates were examined.

Results: The median LMR was 26.7 and it was considered as cut-off value of 26. A positive correlation was found between LMR and Rai Stage. LMR was significantly higher in patients who have an indication for treatment or who died.

Conclusions: In our study, in CLL, LMR has been shown to be over 26 in advanced stages, in relapse or with indication of a treatment. With the increase of LMR, it was found that survival and disease-free gap decreased.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665864PMC
http://dx.doi.org/10.14740/jh730DOI Listing

Publication Analysis

Top Keywords

lymphocyte/monocyte ratio
8
chronic lymphocytic
8
lymphocytic leukemia
8
lmr survival
8
indication treatment
8
lmr
7
prognostic role
4
role lymphocyte/monocyte
4
ratio chronic
4
leukemia background
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!